- Home
- NERV vs BCDA Comparison
NERV vs BCDA Comparison
Compare NERV & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- BCDA
- Stock Information
- Founded
- NERV 2007
- BCDA N/A
- Country
- NERV United States
- BCDA United States
- Employees
- NERV N/A
- BCDA N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- BCDA Health Care
- Exchange
- NERV Nasdaq
- BCDA Nasdaq
- Market Cap
- NERV 12.4M
- BCDA 10.1M
- IPO Year
- NERV 2014
- BCDA N/A
- Fundamental
- Price
- NERV $1.84
- BCDA $2.17
- Analyst Decision
- NERV Hold
- BCDA Strong Buy
- Analyst Count
- NERV 1
- BCDA 1
- Target Price
- NERV $5.00
- BCDA $25.00
- AVG Volume (30 Days)
- NERV 15.2K
- BCDA 63.3K
- Earning Date
- NERV 08-05-2025
- BCDA 05-14-2025
- Dividend Yield
- NERV N/A
- BCDA N/A
- EPS Growth
- NERV N/A
- BCDA N/A
- EPS
- NERV 0.83
- BCDA N/A
- Revenue
- NERV N/A
- BCDA $3,000.00
- Revenue This Year
- NERV N/A
- BCDA N/A
- Revenue Next Year
- NERV N/A
- BCDA N/A
- P/E Ratio
- NERV $2.23
- BCDA N/A
- Revenue Growth
- NERV N/A
- BCDA N/A
- 52 Week Low
- NERV $1.15
- BCDA $1.63
- 52 Week High
- NERV $3.69
- BCDA $5.04
- Technical
- Relative Strength Index (RSI)
- NERV 65.83
- BCDA 47.00
- Support Level
- NERV $1.75
- BCDA $1.80
- Resistance Level
- NERV $1.90
- BCDA $2.31
- Average True Range (ATR)
- NERV 0.12
- BCDA 0.18
- MACD
- NERV 0.04
- BCDA -0.00
- Stochastic Oscillator
- NERV 90.00
- BCDA 53.70
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).